Skip to main content

Résumés des présentations du Symposium de Montpellier

    Références

    1. Bennett, C.L., Tosteson, T.D., Schmitt, B., Weinberg, P.D., Ernstoff, M.S., Ross, S.D.: Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4129 patients using Flutamide. Prostate Cancer and Prostatic Disease, 2: 4–8, 1999.

      Article  Google Scholar 

    2. Bolla, M., Gonzalez, D., Warde, P., et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med., 1997, 337: 295–300.

      PubMed  Article  CAS  Google Scholar 

    3. Brawer, M.K., Stamey, T.A., Fowler, J., Droller, M., Messing, E., Fair, W.R.: Perspectives on prostate cancer diagnosis and treatment: a roundtable. Urol., 2001, 58: 135–140.

      PubMed  Article  CAS  Google Scholar 

    4. Candas, B., Cusan, L., Gomez, et al.: Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate, 2000, 45: 19–35.

      PubMed  Article  CAS  Google Scholar 

    5. Candas, B., Labrie, F.: Unequal decrease of prostate cancer specific death rates through the Province of Quebec between 1991 and 1999. 14th Int. Symposium J. Steroid Biochem. Mol. Biol., Québec, Canada, 2000, P. 133, Abst. 86-P.

    6. Caubet, J.F., Tosteson, T.D., Dong, E.W., Naylon, E.M., Whiting, G.W., Ernstoff, M.S., Ross, S.D.: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urol., 1997, 49: 71–78.

      PubMed  Article  CAS  Google Scholar 

    7. Crawford, E.D., Eisenberger, M.A., McLeod, D.G., et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 1989, 321: 419–424.

      PubMed  CAS  Google Scholar 

    8. Denis, L.J., Keuppens, F., Smith, et al.: Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur. Urol., 1998, 33: 144–151.

      PubMed  Article  CAS  Google Scholar 

    9. Dijkman, G.A., Janknegt, R.A., Dereijke, T.M., Debruyne, F.M.J.: Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J. Urol., 1997, 158: 160–163.

      PubMed  Article  CAS  Google Scholar 

    10. Granfors, T., Modig, H., Damber, J.E., Tomic, R.: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J. Urol., 1998, 159: 2030–2034.

      PubMed  Article  CAS  Google Scholar 

    11. Hanks, G.E., Lu, J., Machtay, et al.: RTOG Protocol 92-02: A Phase III Trial of the Use of Long Term Androgen Suppression Following Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate. 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, USA, 2000, 1284.

    12. Janknegt, R.A., Abbou, C.C., Bartoletti, R., et al.: Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J. Urol., 1993, 149: 77–83.

      PubMed  CAS  Google Scholar 

    13. Labrie, F.: Screening and hormonal therapy of localized prostate cancer show major benefits on survival. Cancer. J. Sci. Am., 2000, 6: S182-S187.

      Google Scholar 

    14. Labrie, F., Bélanger, A., Cusan, L., et al.: Antifertility effects of LHRH agonists in the male. J. Androl., 1980, 1: 209–228.

      CAS  Google Scholar 

    15. Labrie, F., Bélanger, A., Cusan, L., et al.: History of LHRH agonists and combination therapy in prostate cancer. Endocrine-Related Cancer, 1996a, 3: 243–278.

      Article  CAS  Google Scholar 

    16. Labrie, F., Candas, B., Cusan, L., et al.: Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostatespecific antigen. Urol., 1996b, 47: 212–217.

      PubMed  Article  CAS  Google Scholar 

    17. Labrie, F., Candas, B., Dupont, A., et al.: Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 1999a, 38: 83–91.

      PubMed  Article  CAS  Google Scholar 

    18. Labrie, F., Cusan, J., Gomez, J., Levesque, Candas, B.: Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Aging Male, 1999b, 2: 33–43.

      Article  Google Scholar 

    19. Labrie, F., Dupont, A., Bélanger, A: Complete androgen blockade for the treatment of prostate cancer. In de Vita, V.T., Hellman, S. and Rosenberg, S.A., eds. Important Advances in Oncology. Philadelphia, J.B. Lippincott, 1985: 193–217.

      Google Scholar 

    20. Labrie, F., Dupont, A., Suburu, R., et al.: Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J. Urol., 1992, 147: 846–852.

      PubMed  CAS  Google Scholar 

    21. Makinen, T., Tammela, T.L., Hakama, M., et al.: Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J Urol, 2001, 166: 1339–1342

      PubMed  Article  CAS  Google Scholar 

    22. Messing, E.M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E.D., Trump, D.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med., 1999, 341: 1781–1788.

      PubMed  Article  CAS  Google Scholar 

    23. Pilepich, M.V., Caplan, R., Byhardt, et al.: Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J. Clin. Oncol., 1997, 15: 1013–1021.

      PubMed  CAS  Google Scholar 

    24. Prostate Cancer Triallists’ Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet, 2000, 355: 1491–1498.

      Article  Google Scholar 

    25. Shröder, F.H., Maas, P.V.D., Beemsterboer, P., Kruger, A.B., Hoedemaeker, R., Rietbergen, J.: Evaluation of the digital rectal examination as a screening test for prostate cancer. J. Natl. Cancer Inst., 1998, 1817–1823.

    26. Shröder, F.H., Roobol-Bouts, M., Vis, A.N., Kwast, T.V.D., Kranse, R.: Prostate-specific antigen-based early detection of prostate cancervalidation of screening without rectal examination. Urol., 2001, 57: 83–90.

      Article  Google Scholar 

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Résumés des présentations du Symposium de Montpellier. Androl. 12, 207–219 (2002). https://doi.org/10.1007/BF03034967

    Download citation

    \